227 related articles for article (PubMed ID: 20621091)
21. Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases.
Abbott-Banner KH; Page CP
Basic Clin Pharmacol Toxicol; 2014 May; 114(5):365-76. PubMed ID: 24517491
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of phosphodiesterase activity, airway inflammation and hyperresponsiveness by PDE4 inhibitor and glucocorticoid in a murine model of allergic asthma.
Sun JG; Deng YM; Wu X; Tang HF; Deng JF; Chen JQ; Yang SY; Xie QM
Life Sci; 2006 Oct; 79(22):2077-85. PubMed ID: 16875702
[TBL] [Abstract][Full Text] [Related]
23. Inhibitory effect of acetamide-45 on airway inflammation and phosphodiesterase 4 in allergic rats.
Wang K; Shen HH; Chen JC; Chen Z
Acta Pharmacol Sin; 2005 Dec; 26(12):1492-6. PubMed ID: 16297349
[TBL] [Abstract][Full Text] [Related]
24. Relationship between phosphodiesterase type 4 inhibition and anti-inflammatory activity of CI-1044 in rat airways.
Pruniaux MP; Lagente V; Ouaged M; Bertin B; Moreau F; Julien-Larose C; Rocher MN; Leportier C; Martin B; Bouget A; Dubuit JP; Burnouf C; Doherty AM; Bertrand CP
Fundam Clin Pharmacol; 2010 Feb; 24(1):73-82. PubMed ID: 19650853
[TBL] [Abstract][Full Text] [Related]
25. Discovery of oxazole-based PDE4 inhibitors with picomolar potency.
Kuang R; Shue HJ; Xiao L; Blythin DJ; Shih NY; Chen X; Gu D; Schwerdt J; Lin L; Ting PC; Cao J; Aslanian R; Piwinski JJ; Prelusky D; Wu P; Zhang J; Zhang X; Celly CS; Billah M; Wang P
Bioorg Med Chem Lett; 2012 Apr; 22(7):2594-7. PubMed ID: 22401864
[TBL] [Abstract][Full Text] [Related]
26. L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.
Huang Z; Dias R; Jones T; Liu S; Styhler A; Claveau D; Otu F; Ng K; Laliberte F; Zhang L; Goetghebeur P; Abraham WM; Macdonald D; Dubé D; Gallant M; Lacombe P; Girard Y; Young RN; Turner MJ; Nicholson DW; Mancini JA
Biochem Pharmacol; 2007 Jun; 73(12):1971-81. PubMed ID: 17428447
[TBL] [Abstract][Full Text] [Related]
27. A locally active antiinflammatory macrolide (MLD987) for inhalation therapy of asthma.
Hersperger R; Buchheit KH; Cammisuli S; Enz A; Lohse O; Ponelle M; Schuler W; Schweitzer A; Walker C; Zehender H; Zenke G; Zimmerlin AG; Zollinger M; Mazzoni L; Fozard JR
J Med Chem; 2004 Sep; 47(20):4950-7. PubMed ID: 15369399
[TBL] [Abstract][Full Text] [Related]
28. Phosphodiesterase inhibitors in the treatment of inflammatory diseases.
Page CP; Spina D
Handb Exp Pharmacol; 2011; (204):391-414. PubMed ID: 21695650
[TBL] [Abstract][Full Text] [Related]
29. Anti-inflammatory activities of a new series of selective phosphodiesterase 4 inhibitors derived from 9-benzyladenine.
Boichot E; Wallace JL; Germain N; Corbel M; Lugnier C; Lagente V; Bourguignon JJ
J Pharmacol Exp Ther; 2000 Feb; 292(2):647-53. PubMed ID: 10640302
[TBL] [Abstract][Full Text] [Related]
30. Discovery of triazines as potent, selective and orally active PDE4 inhibitors.
Gewald R; Grunwald C; Egerland U
Bioorg Med Chem Lett; 2013 Aug; 23(15):4308-14. PubMed ID: 23806553
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic potential of ASP3258, a selective phosphodiesterase 4 inhibitor, on chronic eosinophilic airway inflammation.
Kobayashi M; Kubo S; Shiraki K; Iwata M; Hirano Y; Ohtsu Y; Takahashi K; Shimizu Y
Pharmacology; 2012; 90(3-4):223-32. PubMed ID: 23038661
[TBL] [Abstract][Full Text] [Related]
32. The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation.
Konrad FM; Bury A; Schick MA; Ngamsri KC; Reutershan J
PLoS One; 2015; 10(4):e0121725. PubMed ID: 25909327
[TBL] [Abstract][Full Text] [Related]
33. Selective phosphodiesterase 4 inhibitors in the treatment of allergy and inflammation.
Smith VB; Spina D
Curr Opin Investig Drugs; 2005 Nov; 6(11):1136-41. PubMed ID: 16312135
[TBL] [Abstract][Full Text] [Related]
34. Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration.
Lunniss CJ; Cooper AW; Eldred CD; Kranz M; Lindvall M; Lucas FS; Neu M; Preston AG; Ranshaw LE; Redgrave AJ; Ed Robinson J; Shipley TJ; Solanke YE; Somers DO; Wiseman JO
Bioorg Med Chem Lett; 2009 Mar; 19(5):1380-5. PubMed ID: 19195882
[TBL] [Abstract][Full Text] [Related]
35. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
Hatzelmann A; Schudt C
J Pharmacol Exp Ther; 2001 Apr; 297(1):267-79. PubMed ID: 11259554
[TBL] [Abstract][Full Text] [Related]
36. Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations.
Draheim R; Egerland U; Rundfeldt C
J Pharmacol Exp Ther; 2004 Feb; 308(2):555-63. PubMed ID: 14610230
[TBL] [Abstract][Full Text] [Related]
37. Antipruritic effect of the topical phosphodiesterase 4 inhibitor E6005 ameliorates skin lesions in a mouse atopic dermatitis model.
Ishii N; Shirato M; Wakita H; Miyazaki K; Takase Y; Asano O; Kusano K; Yamamoto E; Inoue C; Hishinuma I
J Pharmacol Exp Ther; 2013 Jul; 346(1):105-12. PubMed ID: 23674603
[TBL] [Abstract][Full Text] [Related]
38. Palladium-catalyzed cross-coupling reactions for the synthesis of 6, 8-disubstituted 1,7-naphthyridines: a novel class of potent and selective phosphodiesterase type 4D inhibitors.
Hersperger R; Bray-French K; Mazzoni L; Müller T
J Med Chem; 2000 Feb; 43(4):675-82. PubMed ID: 10691693
[TBL] [Abstract][Full Text] [Related]
39. An inhaled phosphodiesterase 4 inhibitor E6005 suppresses pulmonary inflammation in mice.
Kubota S; Watanabe M; Shirato M; Okuno T; Higashimoto I; Machida K; Yokomizo T; Inoue H
Eur J Pharmacol; 2015 Dec; 768():41-8. PubMed ID: 26455478
[TBL] [Abstract][Full Text] [Related]
40. Stable dry powder inhaler formulation of tranilast attenuated antigen-evoked airway inflammation in rats.
Kawabata Y; Aoki Y; Matsui T; Yamamoto K; Sato H; Onoue S; Yamada S
Eur J Pharm Biopharm; 2011 Jan; 77(1):178-81. PubMed ID: 21081161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
